Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.65 |
| ▸ | AHCY | P23526 | 8/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | PI4KA | P42356 | 2/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.51 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3421178 | 0.86 | ADORA2A (0.59) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL10878427 | 0.85 | ADORA2A (0.65) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL886940 | 0.84 | ADORA2A (0.63) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL16603993 | 0.82 | AHCY (0.85) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL16578129 | 0.82 | ADORA2A (0.71) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL2554686 | 0.82 | ADORA2A (0.71) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL2554197 | 0.82 | ADORA2A (0.71) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL28134277 | 0.81 | CYP3A4 (0.64) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL17601885 | 0.81 | CYP3A4 (0.64) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL14963614 | 0.80 | ADORA2A (0.76) | ADORA2AADORA1AHCYALDH1A1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160000937-A1 | MODULATION OF TELOMERE LENGTH IN TELOMERASE POSITIVE CELLS AND CANCER THERAPY | ALT SOLUTIONS, INC. | 2016-01-07 | — | — | US | claimed |
| US-20140065072-A1 | Modulation of Telomere Length in Telomerase Positive Cells and Cancer Therapy | ALT SOLUTIONS INC. (US) | 2014-03-06 | — | — | US | claimed |
| US-8580753-B2 | Modulation of telomere length in telomerase positive cells and cancer therapy | ALT SOLUTIONS INC. (US) | 2013-11-12 | — | — | US | claimed |
| US-20120107863-A1 | MODULATION OF TELOMERE LENGTH IN TELOMERASE POSITIVE CELLS AND CANCER THERAPY | ALT SOLUTIONS INC. (US) | 2012-05-03 | — | — | US | claimed |
| US-8097595-B2 | Modulation of telomere length in telomerase positive cells and cancer therapy | ALT SOLUTIONS, INC. (US) | 2012-01-17 | — | — | US | claimed |
| EP-1594987-B1 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | GENEFORM TECHNOLOGIES LTD (GB) | 2009-05-27 | — | — | EP | claimed |
| EP-1532157-A4 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | METABASIS THERAPEUTICS INC (US) | 2009-02-25 | — | — | EP | claimed |
| EP-1532157-A2 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | Metabasis Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2004037161-A2 | CYCLIC PRODRUGS OF PMEA ONE OF ITS ANALOGUES | METABASIS THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | claimed |
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2021151104-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-29 | — | — | WO | disclosed |
| US-8940313-B2 | Tyrosine-based prodrugs of antiviral agents | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2015-01-27 | — | — | US | disclosed |
| WO-2011133963-A3 | TYROSINE-BASED PRODRUGS OF ANTIVIRAL AGENTS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2011133963-A2 | TYROSINE-BASED PRODRUGS OF ANTIVIRAL AGENTS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2007010285-A2 | CRYSTAL STRUCTURE OF HUMAN SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-25 | — | — | WO | disclosed |
| EP-0754046-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN, William R. (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1995026734-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN WILLIAM R (US) | 1995-10-12 | — | — | WO | disclosed |
| EP-0559744-A1 | COMBINATIONS OF VANILLOID COMPOUNDS AND NUCLEOSIDE ANTIVIRAL COMPOUNDS FOR TREATMENT OF HERPES INFECTIONS | THE PROCTER & GAMBLE COMPANY (US) | 1993-09-15 | — | — | EP | disclosed |
| WO-1992009287-A1 | COMBINATIONS OF VANILLOID COMPOUNDS AND NUCLEOSIDE ANTIVIRAL COMPOUNDS FOR TREATMENT OF HERPES INFECTIONS | THE PROCTER & GAMBLE COMPANY (US) | 1992-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | EIF2AK2, SARS1, ACE | ADORA2A 1744/4885ADORA1 2215/4885AHCY 525/4885 |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | MTAP, PNP, MPO | ADORA2A 128/4885ADORA1 270/4885AHCY 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.